Mitel Networks Corporation (NASDAQ:MITL) reported that financial results for Q3 ended Sept. 30, 2014 topped analysts' expectations, and provided guidance for Q4 in line with Street forecasts. The provider of business communications and collaboration software and services posted Q3 GAAP net loss of $5.3 million, compared with the prior-year period's $1.4 million. Non-GAAP net income was $19 million or $0.18 per share, versus $8.1 million or $0.14 per share in the same quarter the previous year. Revenue was $272.4 million, up from $135 million in the same quarter last year. Analysts polled by Capital IQ were expecting EPS of $0.15 on revenues of $270.54 million.Mitel Networks Corporation (NASDAQ:MITL) said that for Q4, revenue is expected to be in the range of $290 million - $310 million, reflecting recent volatility experienced in foreign currency exchange markets. Non-GAAP EPS is expected to be in the range of $0.27 - $0.30. Analysts are looking for EPS of $0.30 on revenue of $308.02 million. Shares closed at $9.26 with a 52-week range of $5.64 - $11.94.AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for Macrilen (macimorelin), a novel orally-active ghrelin agonist, for use in evaluating adult growth hormone deficiency (AGHD). Based on its review, the FDA has determined that the NDA cannot be approved in its present form.The CRL mentions that the planned analysis of the company's pivotal trial did not meet its stated primary efficacy objective as agreed to in the Special Protocol Assessment agreement letter between the company and the FDA. The CRL further mentioned issues related to the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD. The FDA concluded that, "in light of the failed primary analysis and data deficiencies noted, the clinical trial does not by itself support the indication." To address the deficiencies identified above, the CRL states that the Ccompany will need to demonstrate the efficacy of macimorelin as a diagnostic test for growth hormone deficiency in a new, confirmatory clinical study. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) said it is reviewing the issues in the CRL and evaluating options and future plans for Macrilen.DIRECTV (NASDAQ:DTV) shares were nearly unchanged in recent trade after reporting Q3 earnings and sales that slightly exceeded analysts' views. The provider of digital television entertainment said adjusted earnings rose to $1.33 per diluted share from $1.28 the year earlier compared to the $1.31 average estimate from analysts polled by Capital IQ. Sales rose 6% to $8.37 billion compared to the $8.30 billion consensus. Reported net income fell to $611 million or $1.21 per diluted share from $699 million or $1.28 per share a year ago. DIRECTV (NASDAQ:DTV) shares are trading near the higher end of the 52-week range between $62.64 and $89.46.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
